Medical adhesives developer Resivant Medical announced on Friday that it has received approval from the US Food and Drug Administration (FDA) 510(k) for its first two products, Cutiva Topical Skin Adhesive and Cutiva PLUS Skin Closure System, combining an adhesive mesh patch with high-viscosity Cutiva liquid adhesive.

According to Resivant, its proprietary Cutiva adhesive couples the high-strength bond of super glue with the advantages of crosslinked silicone rubber, providing robust wound closure, enhanced flexibility, durability, and improved patient safety and comfort. It can be dispensed from a single-handed applicator and forms a protective microbial barrier over the incision.

Darren Obrigkeit, CEO of Resivant Medical, said: "The Cutiva platform signifies a fundamental breakthrough in cyanoacrylate adhesive technology for surgical incision and traumatic laceration closure. Cutiva adhesive's unique chemistry maintains a clean incision site without the need for additional dressings and is formulated to significantly reduce the level of exposure to skin irritants."